#ESMO26 #DeLLphi305 Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalum

David Heredia.· @HerediaOncologo · X·2026-10-25 00:03· 13 小时前评分70

正文 · 原文

#ESMO26 #DeLLphi305 Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab

Are we changing prognosis of SCLC?

Yes we are.

Results speak for themselves.

OS 21.1m vs 12.7 m

13 浏览 · 0 赞 · 0 转发 · 0 回复

会议摘要

3821P按 SCLC 对上

Sustained survival with extended follow-up of tarlatamab plus anti-PD-L1 as first-line maintenance (1LM) after chemoimmunotherapy for extensive-stage small cell lung cancer (ES-SCLC): DeLLphi-303 phase 1b study

https://esmocongress.esmo.org

3848P按 SCLC 对上

Cytokine release syndrome in patients receiving tarlatamab for extensive-stage small cell lung cancer: A real-world analysis

https://esmocongress.esmo.org

LBA3按 Presidential Symposium I 对上

Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial

https://esmocongress.esmo.org

来源：David Heredia. · x.com